Antioxidant therapy in the management of acute, chronic and post-ERCP pancreatitis: A systematic review

Figure 1 Individual and pooled relative risk (A), heterogeneity indicators (B), and publication bias indicators (C) for the outcome “prevention of all kinds of pancreatitis” in the studies considering allopurinol vs placebo therapy.

Figure 2 Individual and pooled relative risk (A) and heterogeneity indicators (B) for the outcome “prevention of all kinds of pancreatitis” in the studies considering allopurinol vs placebo therapy.

Figure 3 Individual and pooled relative risk (A) and heterogeneity indicators (B) for the outcome “prevention of moderate pancreatitis” in the studies considering allopurinol vs placebo therapy.

Figure 4 Individual and pooled relative risk (A) and heterogeneity indicators (B) for the outcome “prevention of severe pancreatitis” in the studies considering allopurinol vs placebo therapy.